|
Fingolimod para esclerosis múltiple recurrente-remitente [Fingolimod for relapsing/remitting multiple sclerosis (RRMS)] |
Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A, Valanzasca P |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A, Valanzasca P. Fingolimod para esclerosis múltiple recurrente-remitente. [Fingolimod for relapsing/remitting multiple sclerosis (RRMS)] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N° 271. 2012 Authors' objectives To assess the available evidence on the efficacy, safety and coverage related issues regarding the use of fingolimod in patients with RRMS. Authors' conclusions There is evidence, although scarce, showing that fingolimod would have slightly better benefits than INF and glatiramer acetate. However, most studies use placebo as comparator and the systematic reviews are based on indirect methods to evaluate the efficacy of fingolimod versus the active treatment. It is worth mentioning that the cost of this treatment is high when compared to the benefits and adverse effects observed, and in some countries its use is not recommended. In other countries, its use in patients with RRMS is limited to the price/discount the manufacturer may give, in addition to monitoring its effectiveness in the patients treated to evaluate continuous treatment. On the other hand, there is concern about its safety due to the cardiovascular events and deaths reported since its long-term safety profile is unknown. Fingolimod is proposed as oral monotherapy and disease modifying drug in patients with highly active RRMS and who are refractory to IFN-Beta therapy. Indexing Status Subject indexing assigned by CRD MeSH Humans; Multiple Sclerosis, Relapsing-Remitting; Sphingosine Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32014000295 Date abstract record published 31/01/2014 |
|
|
|